HMTXF (Hemostemix) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 08, 2026)


What is Hemostemix Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Hemostemix's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

HMTXF vs VRTX, REGN, ALNY: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Hemostemix's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemostemix Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemostemix's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Hemostemix's Margin of Safety % (DCF Dividends Based) falls into.


Hemostemix Business Description

Other Exchanges 2VF0:GermanyHEM:Canada
Address 707 - 7th Avenue SouthWest, Suite 1150, Calgary, AB, CAN, T2P 3H6
Hemostemix Inc is a clinical-stage biotechnology company whose principal business is to develop, manufacture, and commercialize blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments. Its product ACP-01 is derived from a patient's own blood and evaluated in clinical research for ischemic conditions, including Cardiovascular Ischemia, Peripheral Arterial Disease (PAD), Chronic Limb Threatening Ischemia (CLTI), and Vascular Dementia.